High materiality7/10
Castle Biosciences initiated with a Buy at Roth Capital
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Roth Capital initiates coverage on CSTL with a Buy; target price $40; current price $22.12.
- Roth Capital Buy on CSTL; target $40.
Key facts
- 01
Target: $40
- 02
Posted price: $22.12
- 03
Analyst firm: Roth Capital
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.